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Umbilical cord blood transplantation can cure pruritic eczematous erup-
tion in a hypohidrotic ectodermal dysplasia with immunodeficiency
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Anhidrotic ectodermal dysplasia and immunodeficiency (EDA-ID) is an X-linked
recessive genodermatosis characterized by severe eczematous eruption, hypohi-
drosis, dental anomalies, alopecia, and immunodeficiency. A 4-month-old Japanese
boy with pruritic eruption on his entire body since birth was referred to our clinic.
Examination revealed diffuse erythema and reddish papules, with scratching
evident on most of the body, which was compatible with atopic dermatitis. A skin
biopsy specimen revealed spongiotic change in the epidermis and perivascular
lymphoid and eosinophilic infiltration in the superficial dermis. Results of appro-
priate laboratory tests confirmed deficient cellular immunity. A pathogenic mutation
c.1167insC was identified in the nuclear factor-kappaB (NF-kB) essential modulator
(NEMO) genes in both the patient and his mother. His mother had been diagnosed
with incontinentia pigmenti by skin biopsy a few months after her birth. His
maternal uncle died from a disorder of unknown etiology when he was 1 month old.
His maternal grandmother and grandmother’s sister were suspected to have had
incontinentia pigmenti from their histories. He was diagnosed as EDA-ID from
clinical features, family history, and mutation analysis of the NEMO gene. The patient
was treated with hydrocortisone cream and a moisturizing agent, which resulted in
minimal improvement of eczema and intense pruritus. When he was 3 years old, he
received an umbilical cord blood transplantation. After the transplantation, his itchy
eruption was gradually getting better. Nonpupuric erythema developed on the trunk
at day 135, and the biopsy specimen showed liquefaction in the dermoepidermal
interface with satellite cell necrosis, compatible with acute GVHD. His eczematous
eruption had almost disappeared, leaving slight xerosis a year after the transplan-
tation. The responsible gene for EDA-ID is the NEMO gene, which is critical for the
activation of NF-kB signaling involved in inflammation, immune responses, and cell
survival.
In male patients, the hypomorphic mutations, in which NEMO function is decreased
but not abolished, generally result in EDA-ID, while larger frameshift and deletion
mutations which completely impair NEMO function cause a lethal condition in male
fetuses. This family had one nucleotide insertion mutation of c.1167insC, which
might sustain some function of the NEMO gene, as previously reported.MARCH 2cial support: None identified.CommerP1105
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Scleromyxedema is a rare idiopathic disorder characterized by dermal mucin
deposition with fibrosis associated with monoclonal gammopathy and systemic
manifestations. Despite some reports of success with numerous agents, there is not
a completely satisfactory therapeutic approach to the scleromyxedema. A 69-year-
old male, previously healthy, presented in a coma without fever or meningeal signs
to the emergency department. He underwent a full neurologic workup and the EEG
showed slow and irregular background activity. The lumbar puncture, MRI and
laboratory studies were normal. He was prescribed valproate, cefotaxime, ampicilin,
acyclovir, and dexamethasone with a slow improvement. He was discharged
without complaints on the fourteenth day. Six months later, the patient presented
a widespread symmetric eruption of tiny waxy monomorphic papules predominat-
ing in the forehead, forearms, and hands. The physical examination also revealed a
diffuse erythema and induration of the skin, leading to decrease the motility
especially of the mouth and the hands. A skin biopsy specimen revealed a diffuse
mucin deposit in the dermis and a marked fibroblastic proliferation. The most
relevant results of the hematologic investigation were IgG monoclonal gammopathy
with l light chains and absence of thyroid disease. The diagnosis of scleromyxedema
was made. The patient was treated with thalidomide 100 mg/day. After 6 months,
there was a discrete improvement, but the treatment had to be stopped because of
neurologic complaints. In the meantime, he suddenly had a loss of consciousness
and he came back to the hospital in a comatose state. This episode was similar to the
previous one. A 5-day course of intravenous immunoglobulin (IVIG; 400 mg/kg/d)
was started and his encephalopathy improved steadily. After completing 6 cycles of
treatment, there was a dramatic skin lesions improvement. We present this case
because (apart of being rare) this case reports an encephalopathy associated with
scleromyxedema and the effectiveness of IVIG in treatment.cial support: None identified.Commer010P1106
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Because eruptive vellus hair cysts were first identified 3 decades ago, treatment for
this condition remains unsatisfactory and time-consuming. We describe a 41-year-
old African American female who presented with a 3-month history of a progressive,
pruritic eruption on her upper chest and neck that was characterized by multiple
dome-shaped, hyperpigmented papules. Skin biopsy of a lesion on her chest
revealed cysts lined by squamous epithelium and containing laminated keratin and
numerous vellus hair shafts. Oral antihistamines and topical corticosteroids did not
relieve her pruritus nor affect the appearance of the lesions. A trial of topical 12%
lactic acid resulted in modest improvement in the appearance of the lesions. Topical
lactic acid is an effective option for eruptive vellus hair cysts in richly pigmented
patients, because surgical options can produce scarring and dyspigmentation.cial support: None identified.CommerP1107
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Background: Chronic idiopathic urticaria (CIU) is a common condition that can be
debilitating, difficult to treat, and sometimes life-threatening. The disease is common
with a lifelong prevalence of 0.5% to 1%. Recent reports have shown that the
disability suffered by CIU patients is similar to that of patients with coronary artery
disease. The treatment of CIU patients can be frustrating, and for those who do not
respond to antihistaminic treatment, other treatment modalities are needed. In
many patients, immunosuppressant medications are required, but these have major
adverse effects, such as renal dysfunction, liver function abnormalities, and anemia.
A safer and more efficacious therapy is clearly needed for CIU.
Aims: To evaluate efficacy and side effects of colchicine in patients with CIU.
Methods: Chart review of patients with diagnosis of CIU based on history, physical
examination, and skin biopsy at the University of Utah between 2002 and 2007.
Results: A total of 36 patients who met criteria for CIU and were treated with
colchicine were identified. Twenty-eight (78%) were women and the mean 6 SD age
was 46 6 15 years. Mean 6 SD duration of the CIU was 41 6 63 months. Fifty-eight
percent had a history of angiedema. Maximum dose of colchicine achieved was 1.5
mg/day with the majority of patients taking 1.2 mg/day. Forty-seven percent were on
treatment for at least 1 month and 42% maintained treatment from[1 to 22 months.
Subjective clinical response to therapy reported as partial (n ¼ 5) or complete (n ¼
15) were found in 55% of patients. Although 39% (n ¼ 14) reported adverse effects
(diarrhea being the most common), only 11 patients (31%) stopped treatment. Of
the 15 patients who had complete clearance, eight patients continue to be
asymptomatic, two patients had recurrence after finishing treatment and switched
to other agents, three patients stopped treatment secondary to side effects, and two
patients had recurrence but responded to a second course of colchicine.
Conclusions: Colchicine is an effective treatment in 55% of our patients. In patients
who had complete response, eight (53%) patients remained clear after tapering of
colchicine. Side effects were mild. These results support the use of colchicine for
patients with CIU unresponsive to standard therapy. Larger, controlled trials will
further investigate colchicine for use in CIU patients.cial support: None identified.CommerJ AM ACAD DERMATOL AB27
